12,526 Shares in CryoPort, Inc. $CYRX Acquired by Savant Capital LLC

Savant Capital LLC bought a new stake in CryoPort, Inc. (NASDAQ:CYRX) in the 2nd quarter, Holdings Channel.com reports. The fund bought 12,526 shares of the company’s stock, valued at approximately $93,000.

A number of other large investors also recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its position in shares of CryoPort by 106.4% during the first quarter. Acadian Asset Management LLC now owns 479,695 shares of the company’s stock worth $2,911,000 after buying an additional 247,288 shares during the period. AQR Capital Management LLC lifted its stake in CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after acquiring an additional 194,482 shares in the last quarter. Trexquant Investment LP boosted its holdings in CryoPort by 57.7% during the 1st quarter. Trexquant Investment LP now owns 377,127 shares of the company’s stock valued at $2,293,000 after acquiring an additional 137,989 shares during the period. Nuveen LLC acquired a new position in CryoPort in the 1st quarter valued at about $743,000. Finally, Cubist Systematic Strategies LLC increased its stake in CryoPort by 109.6% during the first quarter. Cubist Systematic Strategies LLC now owns 226,457 shares of the company’s stock worth $1,377,000 after purchasing an additional 118,420 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Trading Up 4.9%

Shares of NASDAQ:CYRX opened at $8.78 on Friday. CryoPort, Inc. has a 52 week low of $4.58 and a 52 week high of $11.44. The company’s 50 day moving average is $9.39 and its two-hundred day moving average is $8.15. The company has a market cap of $439.61 million, a PE ratio of 6.60 and a beta of 1.58. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. The firm had revenue of $44.23 million during the quarter, compared to the consensus estimate of $41.22 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. Equities analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Leerink Partnrs raised shares of CryoPort from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 6th. BTIG Research raised their price target on shares of CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. KeyCorp upgraded shares of CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price target for the company in a research note on Wednesday, August 6th. UBS Group upped their price objective on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, Needham & Company LLC lifted their target price on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $12.83.

Insider Activity

In other news, Director Robert J. Hariri sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $9.71, for a total transaction of $242,750.00. Following the completion of the transaction, the director directly owned 51,275 shares of the company’s stock, valued at approximately $497,880.25. This represents a 32.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.